IOVA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IOVA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-06), Iovance Biotherapeutics's share price is $8.14. Iovance Biotherapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.
The historical rank and industry rank for Iovance Biotherapeutics's Price-to-Owner-Earnings or its related term are showing as below:
As of today (2024-06-06), Iovance Biotherapeutics's share price is $8.14. Iovance Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.80. Therefore, Iovance Biotherapeutics's PE Ratio for today is At Loss.
As of today (2024-06-06), Iovance Biotherapeutics's share price is $8.14. Iovance Biotherapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.80. Therefore, Iovance Biotherapeutics's PE Ratio without NRI for today is At Loss.
The historical data trend for Iovance Biotherapeutics's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iovance Biotherapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Price-to-Owner-Earnings | Get a 7-Day Free Trial | - | - | - | - | - |
Iovance Biotherapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Price-to-Owner-Earnings | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Iovance Biotherapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Iovance Biotherapeutics's Price-to-Owner-Earnings falls into.
In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Iovance Biotherapeutics's Price-to-Owner-Earnings for today is calculated as
Price-to-Owner-Earnings | = | Share Price | / | Owner Earnings per Share (TTM) |
= | 8.14 | / | -1.77 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iovance Biotherapeutics (NAS:IOVA) Price-to-Owner-Earnings Explanation
For how to get Owner Earnings per Share (TTM), please click.
Thank you for viewing the detailed overview of Iovance Biotherapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.
Merrill A Mcpeak | director | PO BOX 500 (M/S 55-985), 14200 SW KARL BRAUN DRIVE, BEAVERTON OR 97077-0001 |
Wayne P. Rothbaum | director | C/O QUOGUE CAPITAL LLC, 1285 AVENUE OF THE AMERICAS, 35TH FLOOR, NEW YORK NY 10019 |
Wendy L Yarno | director | |
Frederick G Vogt | officer: General Counsel | 2120 HEMLOCK RD., WEST NORRITON PA 19403 |
Iain D. Dukes | director | 112 W. 34TH STREET, 17TH FLOOR, NEW YORK NY 10120 |
Wendy L Dixon | director | |
Ryan D Maynard | director | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080 |
Michael Weiser | director | C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133 |
Igor Bilinsky | officer: Chief Operating Officer | C/O VICAL INCORPORATED, 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121 |
Jean-marc Bellemin | officer: Chief Financial Officer | C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
Michael Swartzburg | officer: VP, Finance | C/O AVALANCHE BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025 |
Athena Countouriotis | director | C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121 |
Finckenstein Friedrich Graf | officer: Chief Medical Officer | 999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070 |
Timothy E Morris | officer: Chief Financial Officer | ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063 |
Maria Fardis | director, officer: President and CEO | C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
From GuruFocus
By GlobeNewswire • 10-20-2023
By Marketwired • 09-22-2023
By Marketwired • 09-27-2023
By Marketwired • 07-21-2023
By Marketwired • 07-10-2023
By GlobeNewswire • 07-11-2023
By sperokesalga sperokesalga • 06-15-2023
By PRNewswire • 12-28-2023
By Marketwired • 10-16-2023
By sperokesalga sperokesalga • 06-20-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.